Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial
Background: A single measurement or a summary of a limited number of measurements of CA125 was considered in the prediction of clinical outcomes for patients with ovarian cancer. We aimed to identify the classes of patients with advanced ovarian cancer based on their CA125 trajectory and to investig...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/7/390 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849733012992819200 |
|---|---|
| author | Chang Yin Josee-Lyne Ethier Mark S. Carey Dongsheng Tu Xueying Zheng |
| author_facet | Chang Yin Josee-Lyne Ethier Mark S. Carey Dongsheng Tu Xueying Zheng |
| author_sort | Chang Yin |
| collection | DOAJ |
| description | Background: A single measurement or a summary of a limited number of measurements of CA125 was considered in the prediction of clinical outcomes for patients with ovarian cancer. We aimed to identify the classes of patients with advanced ovarian cancer based on their CA125 trajectory and to investigate the heterogeneity of clinical outcomes among the patients in the different classes. Methods: CA125 trajectory classes were identified by latent-class mixed models based on values collected within 3 and 6 months post-treatment for 819 women with advanced ovarian cancer enrolled in a randomized trial. Results: Based on their CA125 values during the first 6 months of treatment, the patients with low CA125 levels at baseline that remained low during treatment had the best clinical outcome (a median survival of 83 months and a progression-free survival of 34 months). In contrast, the patients with high CA125 values at baseline with a modest decrease during treatment had the highest risk of death and progression (hazard ratio [95% confidence interval]: 4.83 [3.56, 6.54] for overall survival and 5.15 [3.87, 6.87] for progression-free survival). Conclusions: Longitudinal trajectories of CA125 may provide more direct information for the prognoses of patients with advanced ovarian cancer undergoing chemotherapy treatment. |
| format | Article |
| id | doaj-art-e72fbac9e3524af2a52a265e7c8cabe2 |
| institution | DOAJ |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-e72fbac9e3524af2a52a265e7c8cabe22025-08-20T03:08:09ZengMDPI AGCurrent Oncology1198-00521718-77292025-07-0132739010.3390/curroncol32070390Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical TrialChang Yin0Josee-Lyne Ethier1Mark S. Carey2Dongsheng Tu3Xueying Zheng4Department of Biostatistics, School of Public Health, Fudan University, and the Key Laboratory of Public Health Safety of Ministry of Education, Shanghai 200032, ChinaOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC V6H 3N1, CanadaCanadian Cancer Trials Group, Queen’s University, Kingston, ON K7L 3N6, CanadaDepartment of Biostatistics, School of Public Health, Fudan University, and the Key Laboratory of Public Health Safety of Ministry of Education, Shanghai 200032, ChinaBackground: A single measurement or a summary of a limited number of measurements of CA125 was considered in the prediction of clinical outcomes for patients with ovarian cancer. We aimed to identify the classes of patients with advanced ovarian cancer based on their CA125 trajectory and to investigate the heterogeneity of clinical outcomes among the patients in the different classes. Methods: CA125 trajectory classes were identified by latent-class mixed models based on values collected within 3 and 6 months post-treatment for 819 women with advanced ovarian cancer enrolled in a randomized trial. Results: Based on their CA125 values during the first 6 months of treatment, the patients with low CA125 levels at baseline that remained low during treatment had the best clinical outcome (a median survival of 83 months and a progression-free survival of 34 months). In contrast, the patients with high CA125 values at baseline with a modest decrease during treatment had the highest risk of death and progression (hazard ratio [95% confidence interval]: 4.83 [3.56, 6.54] for overall survival and 5.15 [3.87, 6.87] for progression-free survival). Conclusions: Longitudinal trajectories of CA125 may provide more direct information for the prognoses of patients with advanced ovarian cancer undergoing chemotherapy treatment.https://www.mdpi.com/1718-7729/32/7/390CA125prognosisprogression-free survivaloverall survivaltrajectories |
| spellingShingle | Chang Yin Josee-Lyne Ethier Mark S. Carey Dongsheng Tu Xueying Zheng Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial Current Oncology CA125 prognosis progression-free survival overall survival trajectories |
| title | Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial |
| title_full | Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial |
| title_fullStr | Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial |
| title_full_unstemmed | Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial |
| title_short | Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial |
| title_sort | trajectories of cancer antigen 125 ca125 within 3 and 6 months after the initiation of chemotherapy treatment for advanced ovarian cancer and clinical outcomes a secondary analysis of data from a phase iii clinical trial |
| topic | CA125 prognosis progression-free survival overall survival trajectories |
| url | https://www.mdpi.com/1718-7729/32/7/390 |
| work_keys_str_mv | AT changyin trajectoriesofcancerantigen125ca125within3and6monthsaftertheinitiationofchemotherapytreatmentforadvancedovariancancerandclinicaloutcomesasecondaryanalysisofdatafromaphaseiiiclinicaltrial AT joseelyneethier trajectoriesofcancerantigen125ca125within3and6monthsaftertheinitiationofchemotherapytreatmentforadvancedovariancancerandclinicaloutcomesasecondaryanalysisofdatafromaphaseiiiclinicaltrial AT markscarey trajectoriesofcancerantigen125ca125within3and6monthsaftertheinitiationofchemotherapytreatmentforadvancedovariancancerandclinicaloutcomesasecondaryanalysisofdatafromaphaseiiiclinicaltrial AT dongshengtu trajectoriesofcancerantigen125ca125within3and6monthsaftertheinitiationofchemotherapytreatmentforadvancedovariancancerandclinicaloutcomesasecondaryanalysisofdatafromaphaseiiiclinicaltrial AT xueyingzheng trajectoriesofcancerantigen125ca125within3and6monthsaftertheinitiationofchemotherapytreatmentforadvancedovariancancerandclinicaloutcomesasecondaryanalysisofdatafromaphaseiiiclinicaltrial |